Citations

Institution: Mayo Clinic Clear

Showing 10 of 108135 citations.

Dopamine receptor signaling in the forebrain
Savica, Rodolfo , Benarroch, Eduardo E.

Neurology | July 19, 2014 | Volume: 83 | Issue: 8 | Pages: 758-767

10.1212/wnl.0000000000000719 | PMID 25037203 Get It

Survival After Primary Prevention Implantable Cardioverter-Defibrillator Placement Among Patients With Chronic Kidney Disease
Hess, Paul L. , Hellkamp, Anne S., Sanders, Gillian D, Al‐Khalidi, Hussein R. , Curtis, Lesley H. , Pun, Patrick H. , Curtis, Jeptha P. , Anstrom, Kevin J. , Hammill, Stephen C., Al-Khalidi, Hussein R, Hammill, Bradley G, Al-Khatib, Sana M, Peterson, Eric D. , Hammill, Bradley G. , Al‐Khatib, Sana M.

Circulation: Arrhythmia and Electrophysiology | July 19, 2014 | Volume: 7 | Issue: 5 | Pages: 793-799

10.1161/circep.114.001455 | PMID 25038119 Get It

Background— Guidelines recommend that implantable cardioverter-defibrillator (ICD) candidates have an estimated longevity of ≥1 year. Longevity can be affected by chronic kidney disease (CKD). Methods and Results— Using the National Cardiovascular Data Registry ICD registry linked with the Social Security Death Master File, we assessed the rate of death after primary prevention ICD placement between January 1, 2006, and December 31, 2007, according to CKD stage. Using Cox models, we identified factors associated with death among patients with CKD. Compared with patients without CKD (n=26 056), those with CKD (n=21 226) were older, less commonly men, more often white, and more frequently had comorbid illness. Compared with patients without CKD, patients with a glomerular filtration rate 30 to 60, glomerular filtration rate <30, and end-stage renal disease on dialysis had a higher risk of death after ICD placement (hazard ratio, 2.08; 95% confidence interval, 1.99–2.18; P <0.0001; hazard ratio, 4.20; 95% confidence interval, 3.92–4.50; P <0.0001; and hazard ratio, 4.80; 95% confidence interval, 4.46–5.17; P <0.0001, respectively). Corresponding 1-year death rates were 4.4%, 9.1%, 20.2%, and 22.4%. Among patients with CKD, factors associated with increased risk of death included CKD severity, age >65 years, heart failure symptoms, diabetes mellitus, lung disease, serum sodium <140 mEq/L, atrial fibrillation or flutter, and a lower ejection fraction. Conclusions— The risk of death after primary prevention ICD placement is proportional to CKD severity. Among patients with CKD, several factors are prognostically significant and could inform clinical decision making on primary prevention ICD candidacy.
Liverpool Care Pathway: life-ending pathway or palliative care pathway?
Rady, Mohamed Y, Verheijde, Joseph L., Rady, Mohamed Y

Journal of Medical Ethics | July 19, 2014 | Volume: 41 | Issue: 8 | Pages: 644-644

10.1136/medethics-2014-102314 | PMID 25038086 Get It

Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis
Tefferi, Ayalew , Guglielmelli, Paola , Finke, Christy M. , Wassie, Emnet A, Pieri, Lisa , Gangat, Naseema , Fjerza, Rajmonda, Belachew, Alem A. , Ketterling, Rhett P. , Hanson, Curtis A. , Rambaldi, Alessandro , Thiele, Jüergen, Barbui, Tiziano , Pardanani, Animesh , Lasho, Terra L. , Larson, Dirk R. , Finazzi, Guido , Vannucchi, Alessandro M. , Rambaldi, Alessandro , Ketterling, Rhett P , Guglielmelli, Paola

Blood | July 18, 2014 | Volume: 124 | Issue: 16 | Pages: 2507-2513

10.1182/blood-2014-05-579136 | PMID 25037629 Get It

Key Points Survival in ET is superior to that of PV, regardless of mutational status, but remains inferior to the sex- and age-matched US population. JAK2/CALR/MPL mutational status is prognostically informative in PMF, regarding overall and leukemia-free survival.
Physician Perspective on Incorporation of Oncology Patient Quality-of-Life, Fatigue, and Pain Assessment Into Clinical Practice
Buckner, Jan C. , Sloan, Jeff A. , Hubbard, Joleen M. , Grothey, Axel F, McWilliams, Robert R. , Grothey, Axel

Journal of Oncology Practice | July 18, 2014 | Volume: 10 | Issue: 4 | Pages: 248-253

10.1200/jop.2013.001276 | PMID 24667294 Get It

The authors conclude that single-item measures of pain, fatigue, and QOL can be incorporated into oncology clinical practice with positive implications for patients and physicians without increasing duration of visits or work burden.
Changes in the Care of Non–Small-Cell Lung Cancer After Audit and Feedback: The Florida Initiative for Quality Cancer Care
Lee, Ji‐Hyun , Fulp, William J. , Schreiber, Fred, Brown, R. H. , Levine, Richard M., Cartwright, Thomas H. , Abesada‐Terk, Guillermo, Kim, George P., Alemany, Carlos, Faig, Douglas, Sharp, Philip, Markham, Merry Jennifer , Malafa, Mokenge P. , Jacobsen, Paul B. , Tanvetyanon, Tawee , Brown, Richard H, Abesada-Terk, Guillermo, Sharp, Philip V, Malafa, Mokenge, Markham, Merry J

Journal of Oncology Practice | July 18, 2014 | Volume: 10 | Issue: 4 | Pages: e247-e254

10.1200/jop.2013.001275 | PMID 24737876 Get It

This study is among the first to report on the use of audit and feedback to improve medical oncology practices specifically for the processes of care in NSCLC. A modest but important improvement was observed between 2006 and 2009.
What Is the Gold Standard for Comprehensive Interinstitutional Communication of Perioperative Information for Thyroid Cancer Patients? A Comparison of Existing Electronic Health Records with the Current American Thyroid Association Recommendations
Reis, Laura L. Dos, Tuttle, R. Michael , Alon, Eran E. , Bergman, Donald A., Bernet, Victor , Brett, Elise M., Cobin, Rhoda H., Doherty, Gerard M. , Harris, Jeffrey , Klopper, Joshua , Lupo, Mark A. , Milas, Mira , Macháč, Josef, Orloff, Lisa A. , Randolph, Gregory W. , Ross, Douglas S. , Smallridge, Robert C., Terris, David J. , Mehra, Saral , Scherl, Sophie, Clain, Jason B. , Urken, Mark L. , Lee, Stephanie L. , Mechanick, Jeffrey I. , Randolph, Gregory William , Tufano, Ralph Patrick

Thyroid® | July 18, 2014 | Volume: 24 | Issue: 10 | Pages: 1466-1472

10.1089/thy.2014.0209 | PMID 25036190 Get It

Background: Appropriate management of well-differentiated thyroid cancer requires treating clinicians to have access to critical elements of the patient's presentation, surgical management, postoperative course, and pathologic assessment. Electronic health records (EHRs) provide an effective method for the storage and transmission of patient information, although most commercially available EHRs are not intended to be disease-specific. In addition, there are significant challenges for the sharing of relevant clinical information when providers involved in the care of a patient with thyroid cancer are not connected by a common EHR. In 2012, the American Thyroid Association (ATA) defined the critical elements for optimal interclinician communication in a position paper entitled, “The Essential Elements of Interdisciplinary Communication of Perioperative Information for Patients Undergoing Thyroid Cancer Surgery.” Summary: We present a field-by-field comparison of the ATA's essential elements as applied to three contemporary electronic reporting systems: the Thyroid Surgery e-Form from Memorial Sloan-Kettering Cancer Center (MSKCC), the Alberta WebSMR from the University of Calgary, and the Thyroid Cancer Care Collaborative (TCCC). The MSKCC e-form fulfills 21 of 32 intraoperative fields and includes an additional 14 fields not specifically mentioned in the ATA's report. The Alberta WebSMR fulfills 45 of 82 preoperative and intraoperative fields outlined by the ATA and includes 13 additional fields. The TCCC fulfills 117 of 120 fields outlined by the ATA and includes 23 additional fields. Conclusions: Effective management of thyroid cancer is a highly collaborative, multidisciplinary effort. The patient information that factors into clinical decisions about thyroid cancer is complex. For these reasons, EHRs are particularly favorable for the management of patients with thyroid cancer. The MSKCC Thyroid Surgery e-Form, the Alberta WebSMR, and the TCCC each meet all of the general recommendations for effective reporting of the specific domains that they cover in the management of thyroid cancer, as recommended by the ATA. However, the TCCC format is the most comprehensive. The TCCC is a new Web-based disease-specific database to enhance communication of patient information between clinicians in a Health Insurance Portability and Accountability Act (HIPAA)-compliant manner. We believe the easy-to-use TCCC format will enhance clinician communication while providing portability of thyroid cancer information for patients.
Erythropoietin increases bioavailability of tetrahydrobiopterin and protects cerebral microvasculature against oxidative stress induced by eNOS uncoupling
Santhanam, Anantha Vijay R., Katušić, Zvonimir S. , d’Uscio, Livius V.

Journal of Neurochemistry | July 18, 2014 | Volume: 131 | Issue: 4 | Pages: 521-529

10.1111/jnc.12824 | PMID 25041251 Get It

AbstractThis study was designed to determine whether treatment with erythropoietin (EPO) could protect cerebral microvasculature against the pathological consequences of endothelial nitric oxide (NO) synthase uncoupling. Wild‐type and GTP cyclohydrolase I (GTPCH‐I)‐deficient hph1 mice were administered EPO (1000 U/kg/day, s.c., 3 days). Cerebral microvessels of hph1 mice demonstrated reduced tetrahydrobiopterin (BH4) bioavailability, increased production of superoxide anions and impaired endothelial NO signaling. Treatment of hph1 mice with EPO attenuated the levels of 7,8‐dihydrobiopterin, the oxidized product of BH4, and significantly increased the ratio of BH4 to 7,8‐dihydrobiopterin. Moreover, EPO decreased the levels of superoxide anions and increased NO bioavailability in cerebral microvessels of hph1 mice. Attenuated oxidation of BH4 and inhibition of endothelial NO synthase uncoupling were explained by the increased expression of antioxidant proteins, manganese superoxide dismutase, and catalase. The protective effects of EPO observed in cerebral microvessels of hph1 mice were also observed in GTPCH‐I siRNA‐treated human brain microvascular endothelial cells exposed to EPO (1 U/mL or 10 U/mL; 3 days). Our results suggest that EPO might protect the neurovascular unit against oxidative stress by restoring bioavailability of BH4 and endothelial NO in the cerebral microvascular endothelium. image We demonstrate that treatment with erythropoietin (EPO) could protect cerebral microvasculature against the pathological consequences of endothelial nitric oxide (NO) synthase uncoupling. Our results suggest that EPO might protect the neurovascular unit against oxidative stress by restoring bioavailability of tetrahydrobiopterin (BH4) and endothelial nitric oxide.
Inhibition of DNA Topoisomerase II Selectively Reduces the Threat of Tumorigenicity Following Induced Pluripotent Stem Cell-Based Myocardial Therapy
Wyles, Saranya P. , Oommen, Saji , Maleszewski, Joseph J. , Beraldi, Rosanna, Martinez‐Fernandez, Almudena , Yamada, Satsuki , Terzic, André , Nelson, Timothy J.

Stem Cells and Development | July 18, 2014 | Volume: 23 | Issue: 19 | Pages: 2274-2282

10.1089/scd.2014.0259 | PMID 25036735 Get It

The advent of induced pluripotent stem cell (iPSC) technology creates new opportunities for transplant-based therapeutic strategies. The potential for clinical translation is currently hindered by the risk of dysregulated cell growth. Pluripotent stem cells reprogrammed by three-factor (Sox2, Klf, and Oct4) and four-factor (Sox2, Klf, Oct4, and c-Myc) strategies result in the capacity for teratogenic growth from residual pluripotent progeny upon in vivo transplantation. However, these pluripotent stem cells also have a stage-specific hypersensitivity to DNA-damaging agents that may allow separation of lineage-specific therapeutic subpopulation of cells. We aimed to demonstrate the selective effect of DNA topoisomerase II inhibitor, etoposide, in eliminating pluripotent cells in the early cardiac progenitor population thus decreasing the effect of teratoma formation. Immunodeficient murine hearts were infarcted and received implantation of a therapeutic dose of cardiac progenitors derived from partially differentiated iPSCs. Etoposide-treated cell implantation reduced mass formation in the intracardiac and extracardiac chest cavity compared with the same dose of iPSC-derived cardiac progenitors in the control untreated group. In vivo bioluminescence imaging confirmed the localization and engraftment of transplanted cells in the myocardium postinjection in both groups. Comparatively, the equivalent cell population without etoposide treatment demonstrated a greater incidence and size of teratoma formation. Hence, pretreatment with genotoxic etoposide significantly lowered the threat of teratogenicity by purging the contaminating pluripotent cells, establishing an adjunctive therapy to further harness the clinical value of iPSC-derived cardiac regeneration.
Intradermal penicillin skin test is more likely to be positive compared to prick skin test in patients with a history of penicillin allergy
Park, Miguel

Clinical and Translational Allergy | July 18, 2014 | Volume: 4 | Issue: S3 | Pages: No page available

10.1186/2045-7022-4-s3-p101 Get It